CSPG4 and neoplasm: Several years of promising findings with a variety of approaches based on CSPG4 as a tumour target, together with recent technical, translational and clinical developments in the field of antibody therapeutics for solid tumours, now provide a strong case for revisiting the concept of an antibody modality centred on this promising tumour antigen.